Home/ COVID-19

ESID COVID-19 Statement

Since the start of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, there has been rapid progress with understanding disease clinical phenotypes and biology, improving treatment and implementing vaccination trials. While there remains relatively little published information about the impacts of COVID-19 for patients with Primary Immunodeficiency (PID), data are gradually emerging. The purpose of this statement is to summarise what we know so far and set out ESID’s current guidance for professionals in the PID community in Europe. We will update this statement as evidence emerges.

Joint statement on the current epidemics of new Coronavirus

Together with IPOPI, INGID, APSID, ASID, ARAPID, CIS, LASID, SEAPID we have worked on a joint statement to provide guidance in advising patients with primary immunodeficiency under our care in the current COVID-19 context.

PID Survey update - COVID-19

The Survey summary on COVID-19 in PID patients can be viewed  here.

The COVID Human Genetic Effort

Dear Friends and Colleagues,
Please find here a study proposal on behalf of Jean-Laurent Casanova, Lab of Human Genetics of Infectious Diseases, The Rockefeller University & HHMI, New York - Necker Hospital for Sick Children & INSERM, Paris.

COPID19. Worldwide survey of COVID-19 in PID patients

With the emergence of SARS-CoV-2 and the COVID-19 pandemic, there is an urgent need to understand the impact of infection on immunodeficient individuals. 

May 2021: Managing COVID in patients with Type 1 IFN pathway defects

May Webinar

Date: Tuesday 18th May

Time: 17:30-18:30 CET